See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments
Botanix Pharmaceuticals, a medical dermatology company, released new key findings for a Phase 2 study of its BTX 1503 product.
Botanix Pharmaceuticals (ASX:BOT), a medical dermatology company, released new key findings for a Phase 2 study of its BTX 1503 product.
As quoted in the press release:
Key highlights
• All doses of BTX 1503 were very safe – no serious adverse events or treatment related discontinuations while achieving positive effects on acne lesion reductions
• BTX 1503 as a once daily application had the best performance, which from a compliance and commercial perspective, is the ideal dosing regime
• A strong and consistent impact on inflammatory lesions was seen across the entire study with even greater non-inflammatory lesion reductions
• Australian sites showed clear separation of BTX 1503 5 percent once a day vs vehicle – 40.8 percent vs 26.4 percent for inflammatory and 38.1 percent vs 5.1 percent for non-inflammatory lesions
• Patients in the USA that received vehicle had a high vehicle response which skewed the primary endpoint
Top News
FEATURED STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.